Cost-effectiveness of Prostate Cancer Screening and Treatment

Letters15 November 1993Cost-effectiveness of Prostate Cancer Screening and TreatmentSyed Bilgrami, MD and Bernard Greenberg, MDSyed Bilgrami, MDSearch for more papers by this author and Bernard Greenberg, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-10-199311150-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Dr. Garnick discussed the early treatment of metastatic prostate cancer, total androgen blockade, and the cost of 1 year of flutamide therapy. He stated that 165 000 new cases of prostate cancer are expected to be diagnosed in the United States in 1993, with 25% of patients presenting with stage D2 disease. The early use of total androgen blockade is gaining widespread acceptance in such patients, but it should be noted that the use of flutamide for 1 year as part of total androgen blockade will cost more than 100 million dollars in this country alone. Unfortunately, ...References1. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321:419-24. Google Scholar2. Keuppens F, Denis L, Smith P, Carval HO AP, Newling D, Bond A, et al. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. Cancer. 1990; 66:1045-57. Google Scholar3. Iversen P, Christensen MG, Friis E, Hornbol P, Hvidt V, Iversen HG, et al. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer. 1990; 66:1058-66. Google Scholar4. Beland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, et al. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer. 1990; 66:1074-9. Google Scholar5. Lunglmayr G. A multicenter trial comparing the luteinizing hormone releasing hormone analog zoladex, with zoladex plus flutamide in the treatment of advanced prostate cancer. Eur Urol. 1990; 18(Suppl 3):28-9. Google Scholar6. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol. 1993; 149:77-83. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThe fall in incidence of prostate carcinoma: On the down side of a prostate specific antigen induced peak in incidence--Data from the Utah Cancer Registry 15 November 1993Volume 119, Issue 10Page: 1054-1055KeywordsAndrogensCancer screeningCancer treatmentProstate cancerProstate diseases Issue Published: 15 November 1993 CopyrightCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...